SCD and Parkinson disease: SCD inhibitors for α‐synuclein PD pathology have been developed11, 15 and shown to be particularly effective in crossing the blood–brain barrier and reducing fatty acid desaturation index with good pharmacokinetic properties in rats and Macaca fascicularis monkeys.20